Page last updated: 2024-08-22

ruthenium and ER-Negative PR-Negative HER2-Negative Breast Cancer

ruthenium has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 26 studies

Research

Studies (26)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	11 (42.31)	24.3611
2020's	15 (57.69)	2.80

Authors

Authors	Studies
Chakraborty, A; Koley, TS; Mukherjee, A; Purkait, K	1
Chen, Q; Chen, T; He, L; Li, X; Xu, L	1
Gibson, H; Herroon, MK; Kodanko, JJ; Podgorski, I; Thummel, RP; Toupin, N; Turro, C	1
Li, G; Liu, W; Mei, W; Meng, J; Wang, J; Wang, Z; Wu, Q; Wu, R; Yuan, C	1
Bryszewska, M; Hołota, M; Ionov, M; Javier de la Mata, F; Karolczak, K; Kubczak, M; Maly, M; Michlewska, S; Ortega, P; Skiba, E; Watala, C; Wójkowska, D	1
Bocchetti, M; Ferraro, MG; Irace, C; Misso, G; Montesarchio, D; Paduano, L; Piccolo, M; Riccardi, C; Santamaria, R; Trifuoggi, M	1
Das, R; Paira, P	1
Bryszewska, M; de la Mata, FJ; Ionov, M; Michlewska, S; Ortega, P; Skiba, E; Watala, C; Wójkowska, D	1
Cai, J; Jiang, W; Kourti, M; Westwell, AD	1
Castonguay, A; Golbaghi, G	1
Batista, AA; Carroccia, MC; Cominetti, MR; Correa, RS; Deflon, VM; Farrell, NP; Oliveira, KM; Peterson, EJ	1
Bodman-Smith, K; Daher, CF; Khnayzer, RS; Mansour, N	1
Aquino, LEN; Back, DF; da Silva, JP; de Araujo, MP; Ellena, J; Facchin, G; Fuganti, O; Gondim, ACS; Guimarães, IDL; Kramer, MG; Lopes, LGF; Machado, S; Sousa, EHS; Wohnrath, K	1
Batista, AA; Cominetti, MR; Correa, RS; Graminha, AE; Honorato, J; Menezes, ACS	1
Chao, H; Chen, Y; Ji, L; Liao, X; Lin, M; Luo, D; Zou, S	1
Guevara, M; Kim, HC; Li, Z; Liu, H; Mai, J; Mao, ZW; Mu, C; Shen, H; Shen, J; Wolfram, J; Xie, Y; Zhang, H; Zhang, W	1
Almeida, MAP; Batista, AA; Becceneri, AB; Colina-Vegas, LA; Cominetti, MR; Corrêa, RS; Ellena, J; Graminha, AE; Popolin, CP; Reis, JPB	1
Batista, AA; Becceneri, AB; Castellano, EE; Cominetti, MR; Maistro, EL; Plutin, AM; Popolin, CP	1
Brabec, V; Kasparkova, J; Kostrhunova, H; Novohradsky, V; Pracharova, J; Štarha, P; Trávníček, Z	1
Batista, AA; Cominetti, MR; Graminha, AE; Honorato, J; Luna-Dulcey, L; Menezes, ACS; Naves, MA; Vegas, LC	1
Bohic, S; Bouron, A; Carriere, M; Cloetens, P; da Silva, JC; Fus, F; Jaouen, G; Lee, HZS; Pacureanu, A; Salmain, M; Top, S; Vessières, A; Yang, Y	1
Hansongnern, K; Nhukeaw, T; Ratanaphan, A; Temboot, P	1
Contel, M; Elie, BT; Frik, M; Gonzalo, O; Martínez, A; Marzo, I; Prabha, S; Ramírez de Mingo, D; Ramos, JW; Sadhukha, T; Sanaú, M; Sánchez-Delgado, R	1
Hongthong, K; Ratanaphan, A	1
Amici, A; Ferraro, S; Gambini, V; Hysi, A; Iezzi, M; Lupidi, G; Marchetti, F; Marchini, C; Montani, M; Pazmay, GVB; Pettinari, C; Pettinari, R; Tilio, M	1
Garcia, MH; Gärtner, F; Marques, F; Matos, A; Mendes, N; Morais, TS; Tomaz, AI; Tortosa, F; Valente, A	1

Reviews

2 review(s) available for ruthenium and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Rationally Designed Ruthenium Complexes for Breast Cancer Therapy. Molecules (Basel, Switzerland), 2020, Jan-09, Volume: 25, Issue:2 Topics: Antineoplastic Agents; Coordination Complexes; Female; Humans; Ligands; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Ruthenium; Triple Negative Breast Neoplasms	2020
BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds. Current cancer drug targets, 2016, Volume: 16, Issue:7 Topics: Antineoplastic Agents; BRCA1 Protein; Female; Humans; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Ruthenium; Triple Negative Breast Neoplasms	2016

Other Studies

24 other study(ies) available for ruthenium and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Synthesis, Structure and Cytotoxicity of N,N and N,O-Coordinated Ru Chemistry, an Asian journal, 2021, Nov-15, Volume: 16, Issue:22 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Coordination Complexes; Drug Screening Assays, Antitumor; Humans; meta-Aminobenzoates; Ruthenium; Schiff Bases; Triple Negative Breast Neoplasms; Tumor Cells, Cultured	2021
Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment. Biomaterials, 2022, Volume: 281 Topics: Cell Line, Tumor; Humans; Immunotherapy; Immunotherapy, Adoptive; Killer Cells, Natural; Ruthenium; Triple Negative Breast Neoplasms	2022
Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor-Associated Macrophages. Chemistry (Weinheim an der Bergstrasse, Germany), 2022, Apr-27, Volume: 28, Issue:24 Topics: Cell Line, Tumor; Humans; Immunotherapy; Rhodium; Ruthenium; Triple Negative Breast Neoplasms; Tumor-Associated Macrophages	2022
Novel Chiral Ru(II) Complexes as Potential c-myc G-quadruplex DNA Stabilizers Inducing DNA Damage to Suppress Triple-Negative Breast Cancer Progression. International journal of molecular sciences, 2022, Dec-22, Volume: 24, Issue:1 Topics: Animals; Antineoplastic Agents; Coordination Complexes; DNA; DNA Damage; G-Quadruplexes; Humans; Ruthenium; Triple Negative Breast Neoplasms; Zebrafish	2022
Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study. International journal of pharmaceutics, 2023, Apr-05, Volume: 636 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Computer Simulation; Coordination Complexes; Drug Carriers; Drug Screening Assays, Antitumor; Humans; Mice; Molecular Structure; Ruthenium; Triple Negative Breast Neoplasms	2023
Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem. International journal of molecular sciences, 2023, Mar-30, Volume: 24, Issue:7 Topics: Antineoplastic Agents; Cell Line, Tumor; Fatty Acids, Monounsaturated; Female; Humans; Liposomes; Ruthenium; Triple Negative Breast Neoplasms	2023
GSH resistant, luminescent 2-(pyren-1-yl)-1 Dalton transactions (Cambridge, England : 2003), 2023, Oct-31, Volume: 52, Issue:42 Topics: Antineoplastic Agents; Coordination Complexes; DNA; Humans; Phenanthrolines; Ruthenium; Triple Negative Breast Neoplasms; Tumor Microenvironment	2023
Ruthenium metallodendrimer against triple-negative breast cancer in mice. Nanomedicine : nanotechnology, biology, and medicine, 2023, Volume: 53 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Mice; Ruthenium; Triple Negative Breast Neoplasms	2023
Structural Modifications on CORM-3 Lead to Enhanced Anti-angiogenic Properties Against Triple-negative Breast Cancer Cells. Medicinal chemistry (Shariqah (United Arab Emirates)), 2021, Volume: 17, Issue:1 Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Humans; Organometallic Compounds; Ruthenium; Structure-Activity Relationship; Triple Negative Breast Neoplasms	2021
Ru(II)-Naphthoquinone complexes with high selectivity for triple-negative breast cancer. Dalton transactions (Cambridge, England : 2003), 2020, Nov-25, Volume: 49, Issue:45 Topics: Antineoplastic Agents; Benzoquinones; Cell Death; Cell Proliferation; Coordination Complexes; Humans; MCF-7 Cells; Mitochondria; Reactive Oxygen Species; Ruthenium; Triple Negative Breast Neoplasms	2020
A photoactivatable Ru (II) complex bearing 2,9-diphenyl-1,10-phenanthroline: A potent chemotherapeutic drug inducing apoptosis in triple negative human breast adenocarcinoma cells. Chemico-biological interactions, 2021, Feb-25, Volume: 336 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Coordination Complexes; Drug Screening Assays, Antitumor; Humans; Phenanthrolines; Photochemical Processes; Ruthenium; Triple Negative Breast Neoplasms; Tumor Cells, Cultured	2021
Electrochemical, mechanistic, and DFT studies of amine derived diphosphines containing Ru(II)-cymene complexes with potent Dalton transactions (Cambridge, England : 2003), 2020, Nov-25, Volume: 49, Issue:45 Topics: Amines; Antineoplastic Agents; Coordination Complexes; Cymenes; Density Functional Theory; Electrochemistry; HeLa Cells; Humans; Phosphines; Ruthenium; Triple Negative Breast Neoplasms	2020
A novel ruthenium(ii) gallic acid complex disrupts the actin cytoskeleton and inhibits migration, invasion and adhesion of triple negative breast tumor cells. Dalton transactions (Cambridge, England : 2003), 2021, Jan-07, Volume: 50, Issue:1 Topics: Actin Cytoskeleton; Animals; Antineoplastic Agents; Apoproteins; Biphenyl Compounds; Cell Adhesion; Cell Line; Cell Movement; Cell Survival; Coordination Complexes; Gallic Acid; Humans; Mice; Picrates; Pyridines; Ruthenium; Serum Albumin, Bovine; Transferrin; Triple Negative Breast Neoplasms	2021
Ruthenium(II) complexes as bioorthogonal two-photon photosensitizers for tumour-specific photodynamic therapy against triple-negative breast cancer cells. Chemical communications (Cambridge, England), 2021, May-04, Volume: 57, Issue:36 Topics: Antineoplastic Agents; Cell Proliferation; Coordination Complexes; Drug Screening Assays, Antitumor; Female; Humans; Photochemotherapy; Photons; Photosensitizing Agents; Ruthenium; Triple Negative Breast Neoplasms	2021
A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer. Nano letters, 2017, 05-10, Volume: 17, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Coordination Complexes; Drug Carriers; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Liposomes; Mice; Mice, Nude; Pyridines; Ruthenium; Theranostic Nanomedicine; Tissue Distribution; Triple Negative Breast Neoplasms	2017
Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells. PloS one, 2017, Volume: 12, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coordination Complexes; Crystallography, X-Ray; DNA; Female; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Ruthenium; Triple Negative Breast Neoplasms; Tumor Stem Cell Assay	2017
The trans-[Ru(PPh Journal of inorganic biochemistry, 2018, Volume: 186 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coordination Complexes; Female; Humans; Male; Mice; Ruthenium; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2018
Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells. Dalton transactions (Cambridge, England : 2003), 2018, Sep-11, Volume: 47, Issue:35 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Drug Screening Assays, Antitumor; Humans; Membrane Potential, Mitochondrial; Molecular Structure; Osmium; Phenanthrolines; Ruthenium; Triple Negative Breast Neoplasms	2018
Transport of the Ruthenium Complex [Ru(GA)(dppe) Molecular pharmaceutics, 2019, 03-04, Volume: 16, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Biological Transport, Active; Cell Line, Tumor; Cell Movement; Cisplatin; Coordination Complexes; DNA, Neoplasm; Female; Gallic Acid; Humans; Ligands; Molecular Structure; Neoplasm Invasiveness; Receptors, Transferrin; Ruthenium; Serum Albumin, Human; Transferrin; Triple Negative Breast Neoplasms	2019
Intracellular Localization of an Osmocenyl-Tamoxifen Derivative in Breast Cancer Cells Revealed by Synchrotron Radiation X-ray Fluorescence Nanoimaging. Angewandte Chemie (International ed. in English), 2019, 03-11, Volume: 58, Issue:11 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Coordination Complexes; Female; Humans; Hydrogen-Ion Concentration; Iron; Ligands; Molecular Imaging; Molecular Probes; Nanostructures; Organometallic Compounds; Osmium; Radiography; Ruthenium; Static Electricity; Synchrotrons; Tamoxifen; Triple Negative Breast Neoplasms; X-Rays	2019
Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine. BMC cancer, 2014, Feb-07, Volume: 14 Topics: Antineoplastic Agents; Cell Cycle; Female; Humans; Intercalating Agents; MCF-7 Cells; Pyridines; Ruthenium; Triple Negative Breast Neoplasms; Ubiquitin-Protein Ligases	2014
In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. Journal of medicinal chemistry, 2014, Dec-11, Volume: 57, Issue:23 Topics: Animals; Antineoplastic Agents; Coordination Complexes; Female; HEK293 Cells; Humans; In Vitro Techniques; Mice, Inbred NOD; Mice, SCID; Organometallic Compounds; Phosphoranes; Ruthenium; Solubility; Triple Negative Breast Neoplasms; Water	2014
The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells. Pharmacological research, 2016, Volume: 107 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Kidney; Liver; Mice; Organometallic Compounds; Ruthenium; T-Lymphocytes, Regulatory; Triple Negative Breast Neoplasms; Tumor Burden	2016
In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model. Anti-cancer agents in medicinal chemistry, 2017, Volume: 17, Issue:1 Topics: Animals; Antineoplastic Agents; Breast; Cell Death; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Organometallic Compounds; Ruthenium; Triple Negative Breast Neoplasms	2017